Novartis AG (NYSE:NVS; SIX:NOVN) has invested over $9 billion annually in R&D over the last three years and has a stocked pipeline to show for it. The 16 NMEs in Phase III or registration shown below span five disease areas. The pharma plans to file regulatory applications for five of the programs this year and three next year. Not shown are 14 marketed drugs in Phase III or registration for additional indications, including five from last week's deal with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). In addition, six